Stock Price Quote

NEULAND LABORATORIES LTD.

NSE : NEULANDLABBSE : 524558ISIN CODE : INE794A01010Industry : Pharmaceuticals & DrugsHouse : Private
BSE19876.80180.05 (+0.91 %)
PREV CLOSE ( ) 19696.75
OPEN PRICE ( ) 19696.75
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 651
TODAY'S LOW / HIGH ( )19696.75 20040.00
52 WK LOW / HIGH ( )11500 24235.05
NSE19836.00136 (+0.69 %)
PREV CLOSE( ) 19700.00
OPEN PRICE ( ) 19700.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 4187
TODAY'S LOW / HIGH( ) 19598.00 19954.00
52 WK LOW / HIGH ( )11500 24225
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 07-01 1984
Management Info
Davuluri Rama Mohan Rao - Chairman Davuluri Saharsh Rao - Managing Director
Registered Office

Address 11th Floor (5th Office Level),Phoenix I V Y Building, Plot No.573 A- I I I,Road No. 82, Jubilee Hills,
Hyderabad,
Telangana-500033

Phone 040-67611600 / 67611700

Email neuland@neulandlabs.com

Website www.neulandlabs.com

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE

NEWS

04Nov Neuland Laboratories informs about pre
Neuland Laboratories has informed that it enclosed copies of newspaper a..
15Sep Neuland Labs starts operations at firs
Neuland Laboratories has commenced operations at its first commercial pe..
15Sep Neuland Laboratories informs about pre
Neuland Laboratories has informed that it enclosed a Press Release title..
08Sep Neuland Lab’s Board approves Rs 126 cr
Neuland Laboratories’ Board has approved capital expenditure (capex) of..
08Sep Neuland Lab surges as its Board approv
Neuland Laboratories is currently trading at Rs. 23661.70, up by 789.35..

Financials

in Millions
QTR Sep 26 ANNUAL 26
Net Profit511.283631.05
Gross Profit 684.81 4877.34
Operating Profit 1045.546034.09
Net Sales 4496.5720229.85

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Divi's Laboratories (BSE)
peergroup  11080.25 (7.52%)
M.Cap ( in Cr)294145.82
Abbott India (BSE)
peergroup  26684.90 (1.31%)
M.Cap ( in Cr)56703.55
Procter&Gamble Healt (BSE)
peergroup  5709.90 (2.97%)
M.Cap ( in Cr)9478.08
Acutaas Chemicals (BSE)
peergroup  3929.30 (3.75%)
M.Cap ( in Cr)32169.62
CORONA Remedies (BSE)
peergroup  2531.10 (3.78%)
M.Cap ( in Cr)15480.23

Shareholding Pattern

PROMOTERS 32.26%
NON-INSTITUTION 29.55%
MUTUAL FUNDS/UTI 12.45%
FI/BANKS/INSURANCE 1.35%
GOVERNMENT 0%
FII 0%

About Neuland Laboratories Ltd.

Neuland Laboratories Ltd. was incorporated in the year 1984. Its today's share price is 19876.8. Its current market capitalisation stands at Rs 25501.71 Cr. In the latest quarter, company has reported Gross Sales of Rs. 20229.85 Cr and Total Income of Rs.20531.49 Cr. The company's management includes Mauricio Futran, Ravi Shankar Gopinath, Pallavi Joshi Bakhru, Sugata Sircar, Prasad Raghava Menon, Homi Rustam Khusrokhan, Davuluri Saharsh Rao, Davuluri Sucheth Rao, Davuluri Rama Mohan Rao, Sarada Bhamidipati.

It is listed on the BSE with a BSE Code of 524558 , NSE with an NSE Symbol of NEULANDLAB and ISIN of INE794A01010. It's Registered office is at 11th Floor (5th Office Level),Phoenix I V Y Building, Plot No.573 A- I I I,Road No. 82, Jubilee HillsHyderabad-500033, Telangana. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are KS Aiyar & Co, MSKA & Associates, MSKA & Associates LLP, Walker Chandik & Co LLP, Walker Chandiok & Co LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by ●●● Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.